Heron Therapeutics Inc (NASDAQ:HRTX)

12.47
Delayed Data
As of May 22
 -0.22 / -1.73%
Today’s Change
6.51
Today|||52-Week Range
16.49
+23.96%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$369.5M

Company Description

Heron Therapeutics, Inc. is a pharmaceutical company. It designs and commercializes of polymer technologies for pharmaceutical and other applications. The company develops products using its proprietary Biochronomer polymer based drug delivery technology. Its primary focus is on its product APF530, for the prevention of chemotherapy induced nausea and vomiting. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bioerodible, injectable and implantable delivery systems. Its Biochronomer technology is applicable to a range of therapeutics areas, including prevention of nausea and vomiting, pain management, control of inflammation and treatment of ophthalmic diseases. The company was founded in February 1983 and is headquartered in Redwood City, CA

Contact Information

Heron Therapeutics, Inc.
123 Saginaw Drive
Redwood City California 94063
P:(650) 366-2626
Investor Relations:
(858) 703-6063

Employees

Shareholders

Other institutional67.16%
Individual stakeholders6.27%
Mutual fund holders28.84%

Top Executives

Barry D. QuartChief Executive Officer & Director
Robert H. RosenPresident, Director & Chief Commercial Officer
Brian G. DrazbaVP, Chief Financial & Accounting Officer
Paul G. MarshallSenior Vice President-Technical Operations
Esmé c. SmithSecretary, General Counsel & Vice President

To view my watchlist

Not a member yet?

Sign up now for a free account